TSE:4536Pharmaceuticals
Assessing Santen Pharmaceutical (TSE:4536) Valuation After Nine Month Declines In Sales And Net Income
Why Santen Pharmaceutical’s Latest Earnings Matter for Shareholders
Santen Pharmaceutical (TSE:4536) has put fresh numbers on the table, reporting nine month sales of ¥210,763 million and net income of ¥21,816 million, both below the prior year’s levels.
Earnings per share from continuing operations also softened, with basic EPS at ¥66.16 and diluted EPS at ¥66.05, compared with ¥78.21 and ¥77.98 a year earlier. This represents a shift many investors are now reassessing.
See our latest...